Company: NDRA
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001654954-25-011797
Chunk: 4

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 1.02
Chunk 4
---
Item 1.02 Termination of a Material Definitive Agreement.

As previously disclosed, on February 14, 2024, the Company entered into an At-The-Market Issuance Sales Agreement (the “ ATM Agreement”) with Ascendiant Capital Markets, LLC (“ Ascendiant”) with respect to an “at-the-market” equity offering under which the Company could offer and sell, from time to time at the Company’s discretion, shares of its common stock having an aggregate offering price of up to $6.2 million, through Ascendiant as its sales agent.

On October 13, 2025, the Company delivered written notice to Ascendiant to terminate the ATM Agreement, effective immediately.

The description of the ATM Agreement contained in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of the ATM Agreement filed as Exhibit 1.2 to the Company’s Registration Statement on Form S-3 filed on February 14, 2024.

Item 3.02 Unregistered Sales of Equity Securities.